Qyuns Therapeutics Co Ltd
Qyuns Therapeutics Co Ltd is a biotechnology company engaged in pharmaceuticals and medical research, primarily operating in the healthcare sector.
Business. Qyuns Therapeutics Co Ltd (2509.HK) is a biotechnology and medical research company listed on the Hong Kong Stock Exchange. The firm operates within the healthcare sector, focusing on pharmaceuticals and medical research activities. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not provided in the available data. Consequently, the company is described at the industry level as a participant in the biotechnology and medical research field.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Qyuns Therapeutics Co Ltd (2509.HK) is a biotechnology and medical research company listed on the Hong Kong Stock Exchange. The firm operates within the healthcare sector, focusing on pharmaceuticals and medical research activities. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not provided in the available data. Consequently, the company is described at the industry level as a participant in the biotechnology and medical research field.
Qyuns Therapeutics has a market capitalization of 3.66 billion CNY, with a current market price of 16.28 CNY per share. The company's shares are fully diluted, with no additional shares outstanding beyond the basic shares of 224,567,600. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
Profitability and return metrics are not available in the valuation snapshot, and no industry-specific preferred metrics are provided in the industry configuration. As a result, a direct comparison to cohort medians is not possible at this time.
The company's revenue concentration and geographic exposure are not disclosed in the available data. No segment-specific financials or geographic breakdowns are provided in the input data.
Analyst estimates indicate a strong consensus with a mean price target of 33.00 CNY, which is significantly higher than the current market price of 16.28 CNY. The mean recommendation is 2.00, indicating a "Buy" rating, with one analyst issuing a "Buy" recommendation and none issuing a "Strong Buy" or "Hold".
Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and no going-concern language in source documents. The company is currently assessed as having low dilution risk, with no dilution potential identified in the basic shares outstanding. No recent filings or transcripts are available to provide insight into recent company events or strategic developments.
- The company is undervalued relative to analyst price targets, with a mean target of 33.00 CNY versus a current market price of 16.28 CNY.
- Analysts have issued a "Buy" rating, with one analyst recommending a "Buy" and no "Strong Buy" or "Hold" ratings.
- Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language in source documents.
- The company has low dilution risk, with no additional shares outstanding beyond the basic shares.
- No segment or geographic revenue breakdown is available, limiting visibility into business diversification.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue ¥807.0M, +408,2% YoY; Operating income +201,0% YoY.
- ▍Revenue ¥807.0M, +408,2% YoY
- ▍Operating income +201,0% YoY
- ▍Net income +193,7% YoY
- ▍Free cash flow +204,1% YoY
- ▍Net margin 39.0%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,88 |
| Revenue | —no estimate | —no estimate | 535,0M CNY |
| Operating income | —no estimate | —no estimate | 207,0M CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Qyuns Therapeutics Co Ltd Market data — financials · 2026-05-26
- Qyuns Therapeutics Co Ltd Market data — analyst estimates · 2026-05-26